The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group； W is a direct bond or -NH-； T, U, and V are independently of each other selected from C and N； R2 is H or a halo； m is 1 or 2； X is a carbon, a nitrogen, or an oxygen； Y is C or N； Z is a direct bond or a carbon； R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group； n is 1 or 2； and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.
